294 reports of this reaction
2.1% of all FONDAPARINUX SODIUM reports
#8 most reported adverse reaction
DEEP VEIN THROMBOSIS is the #8 most commonly reported adverse reaction for FONDAPARINUX SODIUM, manufactured by Mylan Institutional LLC. There are 294 FDA adverse event reports linking FONDAPARINUX SODIUM to DEEP VEIN THROMBOSIS. This represents approximately 2.1% of all 13,905 adverse event reports for this drug.
Patients taking FONDAPARINUX SODIUM who experience deep vein thrombosis should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DEEP VEIN THROMBOSIS is a less commonly reported adverse event for FONDAPARINUX SODIUM, but still significant enough to appear in the safety profile.
In addition to deep vein thrombosis, the following adverse reactions have been reported for FONDAPARINUX SODIUM:
The following drugs have also been linked to deep vein thrombosis in FDA adverse event reports:
DEEP VEIN THROMBOSIS has been reported as an adverse event in 294 FDA reports for FONDAPARINUX SODIUM. This does not prove causation, but indicates an association observed in post-market surveillance data.
DEEP VEIN THROMBOSIS accounts for approximately 2.1% of all adverse event reports for FONDAPARINUX SODIUM, making it a notable side effect.
If you experience deep vein thrombosis while taking FONDAPARINUX SODIUM, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.